Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, diazoxide choline controlled-release (DCCR), a tablet for the treatment of Prader-Willi Syndrome (PWS), is entering into late-stage clinical development. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was founded in 1999 and is based in Redwood City, California.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Phone650-213-8444
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.45 million
Profitability
Miscellaneous
Employees18
Next Earnings Date4/1/2019 (Estimated)
OptionableNot Optionable
Soleno Therapeutics (NASDAQ:SLNO) Frequently Asked Questions
What is Soleno Therapeutics' stock symbol?
Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO."
When did Soleno Therapeutics' stock split? How did Soleno Therapeutics' stock split work?
Soleno Therapeutics shares reverse split before market open on Friday, October 6th 2017. The 1-5 reverse split was announced on Thursday, October 5th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 5th 2017. An investor that had 100 shares of Soleno Therapeutics stock prior to the reverse split would have 20 shares after the split.
How were Soleno Therapeutics' earnings last quarter?
Soleno Therapeutics Inc (NASDAQ:SLNO) released its earnings results on Thursday, November, 15th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.11. View Soleno Therapeutics' Earnings History.
When is Soleno Therapeutics' next earnings date?
What price target have analysts set for SLNO?
3 Wall Street analysts have issued 12 month target prices for Soleno Therapeutics' shares. Their predictions range from $4.00 to $14.00. On average, they anticipate Soleno Therapeutics' share price to reach $7.6667 in the next twelve months. This suggests a possible upside of 356.3% from the stock's current price. View Analyst Price Targets for Soleno Therapeutics.
What is the consensus analysts' recommendation for Soleno Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Soleno Therapeutics.
What are Wall Street analysts saying about Soleno Therapeutics stock?
Here are some recent quotes from research analysts about Soleno Therapeutics stock:
- 1. According to Zacks Investment Research, "Soleno Therapeutics Inc. is a healthcare company. It develops and commercializes diagnostics, devices and therapeutics addressing unmet medical needs. The Company offers products consists of CoSense end-tidal carbon monoxide Monitor, NeoPIP Infant Resuscitator and Accessories and Serenz Nasal Relief. Soleno Therapeutics Inc., formerly known as Capnia Inc., is based in Vancouver, Canada. " (11/8/2018)
- 2. Maxim Group analysts commented, "Soleno announced that it will present two poster presentations on 57 th Athens, Greece. The late-breaking posters will show PK and clinical data as well as the glycemic impact of diazoxide chloride controlled release (DCCR) use, long- term, in Prader-Willi Syndrome (PWS). Conclusion: We view the posters as an opportunity to showcase the potential benefit of DCCR in PWS in the EU. Focus remains on the Phase 3 trial of DCCR in PWS which is enrolling, data in 1H19." (9/17/2018)
Has Soleno Therapeutics been receiving favorable news coverage?
News stories about SLNO stock have been trending positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Soleno Therapeutics earned a daily sentiment score of 2.7 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near term.
Who are some of Soleno Therapeutics' key competitors?
Some companies that are related to Soleno Therapeutics include Fonar (FONR), Stereotaxis (STXS), BioSig Technologies (BSGM), Edap Tms (EDAP), IRIDEX (IRIX), Second Sight Medical Products (EYES), Viveve Medical (VIVE), Precision Optics (PEYE), Digirad (DRAD), ENDRA Life Sciences (NDRA), Non-Invasive Monitoring Systems (NIMU), Vaso (VASO), CHF Solutions (CHFS), Nexeon Medsystems (NXNN) and Reshape Lifesciences (RSLS).
What other stocks do shareholders of Soleno Therapeutics own?
Who are Soleno Therapeutics' key executives?
Soleno Therapeutics' management team includes the folowing people:
- Dr. Anish Bhatnagar, Pres, CEO & Director (Age 49)
- Mr. Anthony Wondka, Sr. VP of R&D (Age 57)
- Mr. David D. O'Toole, Consultant (Age 60)
- Mr. Jonathan R. Wolter, CFO & Principal Accounting Officer (Age 69)
- Dr. Neil M. Cowen Ph.D., MBA, Sr. VP of Drug Devel.
Who are Soleno Therapeutics' major shareholders?
Soleno Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Fosun International Ltd (0.84%) and Trellus Management Company LLC (0.79%). Company insiders that own Soleno Therapeutics stock include Edgar Engleman, Jack W Schuler, Larry N Feinberg and Technology Partners Fund Vii L. View Institutional Ownership Trends for Soleno Therapeutics.
Which major investors are buying Soleno Therapeutics stock?
SLNO stock was bought by a variety of institutional investors in the last quarter, including Fosun International Ltd and Trellus Management Company LLC. Company insiders that have bought Soleno Therapeutics stock in the last two years include Edgar Engleman, Jack W Schuler and Larry N Feinberg. View Insider Buying and Selling for Soleno Therapeutics.
How do I buy shares of Soleno Therapeutics?
Shares of SLNO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Soleno Therapeutics' stock price today?
One share of SLNO stock can currently be purchased for approximately $1.68.
How big of a company is Soleno Therapeutics?
Soleno Therapeutics has a market capitalization of $36.01 million and generates $1.45 million in revenue each year. The company earns $-15,660,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis. Soleno Therapeutics employs 18 workers across the globe.
What is Soleno Therapeutics' official website?
How can I contact Soleno Therapeutics?
Soleno Therapeutics' mailing address is 1235 RADIO ROAD SUITE 110, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-213-8444 or via email at [email protected]
MarketBeat Community Rating for Soleno Therapeutics (NASDAQ SLNO)
MarketBeat's community ratings are surveys of what our community members think about Soleno Therapeutics and other stocks. Vote "Outperform" if you believe SLNO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLNO will underperform the S&P 500 over the long term. You may vote once every thirty days.
